Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

BackgroundAtezolizumab+bevacizumab (AB) and lenvatinib have been proposed as first-line treatment options for patients with advanced hepatocellular carcinoma (HCC), but comparative efficacy and associated factors are controversial.Materials and methodsThis real-world multicenter study analysed patie...

Full description

Bibliographic Details
Main Authors: Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, Hee Sun Cho, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Heechul Nam, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
HCC
atezolizumab plus bevacizumab
lenvatinib
residual liver function
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1372007/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1372007/full

Similar Items